Immunophenotyping is employed to help diagnose and classify a leukemia or lymphoma and also detect leukocyte cancer cells that remain after treatment or disease relapse.
To do the test, a blood sample will be drawn from a vein in your arm or sometimes a bone marrow, tissue biopsy, or fluid sample collected by a health practitioner.
The presence of certain antigens that are identified by immunophenotyping require expertise to interpret. The markers will help characterize the abnormal cells present (if any).
It must be kept in mind that each person’s condition will be unique while findings represent comparisons to “normal” results and to known antigen associations with leukemias and lymphomas.
Abnormal immunophenotype profiles are usually present in: acute myelogenous leukemia (or acute myeloid leukemia), acute lymphoblastic leukemia, chronic lymphocytic or myelocytic leukemias, B-cell and T-cell non-Hodgkin lymphomas, erythroleukemia (RBC leukemia), megaloblastic leukemia (platelets), and multiple myeloma.
Keywords: Immunophenotyping, Immunophenotyping by Flow Cytometry, Immunohistochemistry